Trump Administration Proposes Rule to Cut Medicare Drug Prices

The Trump administration proposed a new rule on Thursday that aims to prevent hospitals from charging markups on discounted drugs for Medicare patients, a move estimated to save consumers $1.1 billion in the upcoming year, according to The Associated Press.

This proposed regulation specifically targets hospitals participating in the 340B program, which allows them to purchase outpatient prescription drugs at reduced prices. Currently, many hospitals bill insurers at rates significantly higher than their acquisition costs, pocketing the difference and leading to increased patient expenses. The Centers for Medicare & Medicaid Services intends to revise the reimbursement formula for hospitals in this program to lower costs for patients.

This initiative is part of the Republican administration's broader effort to address healthcare affordability during an election year, highlighting its commitment to alleviating financial burdens on U.S. families facing rising medical expenses. Despite several proposed cost-saving measures, the ultimate savings are uncertain due to the intricate nature of the U.S. healthcare system.

The American Hospital Association has voiced opposition to the proposed rule, with Ashley Thompson, the group's senior vice president for public policy analysis and development, stating that it would exacerbate financial difficulties for its members. Thompson warned that such proposals could compromise hospitals' capacity to sustain essential services and ensure continued access to care for beneficiaries of the 340B program. A potential decrease in hospital revenue could also negatively impact the communities these institutions serve. The 340B program, originally established to enable healthcare providers to expand their resources and serve more patients, has been a focal point of intense lobbying efforts.